Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

(MedPage Today) — The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced.
The rapid-acting L-type calcium channel blocker is indicated…

Source link : https://www.medpagetoday.com/cardiology/arrhythmias/119016

Author :

Publish date : 2025-12-15 19:08:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

Novel Pills Promising in Relapsed/Refractory Multiple Myeloma

FDA Approves Uplizna for Generalized Myasthenia Gravis

Related Posts

Tirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics

Gout and Its Comorbidities

Combination Model May Improve Diagnosis of Serious Respiratory Infections

High-Fat Cheese May Have Cognitive Benefit, Study Suggests

Four Republicans Defy House Speaker to Force Vote on Extending ACA Subsidies

Two Extended-Release Buprenorphine Doses Effective in High-Risk Opioid Use Disorder

Tirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics

Gout and Its Comorbidities

Combination Model May Improve Diagnosis of Serious Respiratory Infections

High-Fat Cheese May Have Cognitive Benefit, Study Suggests

Four Republicans Defy House Speaker to Force Vote on Extending ACA Subsidies

Two Extended-Release Buprenorphine Doses Effective in High-Risk Opioid Use Disorder

Major Developments in Psoriatic Disease

ADHD App Cleared; Anti-Inflammatories for Depression; Charges Over Adderall Scripts

Categories

Archives